Börskollen - Aktier, fonder och ekonominyheter
Börskollen
Bilval: Kinesiska elbilar rasar i pris – modellen har tappat 12 700 kronor i månaden i 3 år

Analyser av ODI Pharma

Kurs från TradingView
Visa mer ▼
StartNyheterPressreleaserRiktkurserInsynshandelBlankningAnalyserBloggarVideosPodcasts

ODI Pharma: Increased Import Quota in Poland Set to Drive Growth in 2025 - Analyst Group

ODI Pharma AB:s (”ODI Pharma” or the ”Company”) past two quarters has been affected by import restrictions in Poland, which is now resolved,...

Analyst Group • 07 mar 2025 11:39

Analyst Group Comment on ODI Pharma’s Quarterly Report

ODI Pharma AB (“ODI Pharma” or the ”Company”) published on February 27th the company’s Q2-report for 2024/2025.

Analyst Group • 03 mar 2025 10:35

Comment on ODI Pharma’s Update on Poland’s Expanding Medical Cannabis Market - Analyst Group

On December 4th ODI Pharma provided an update regarding Poland’s expanding medical cannabis market.

Analyst Group • 05 dec 2024 07:27

ODI Pharma: Ready to Capitalize on Rapid Market Growth in Poland - Analyst Group

ODI Pharma AB:s (”ODI Pharma” or the ”Company”) latest quarter was affected by import restrictions in Poland, which has been resolved after ...

Analyst Group • 03 dec 2024 07:29

Analyst Group Comment on ODI Pharma’s Quarterly Report

ODI Pharma published on November 22nd the company’s Q1-report for 2024/2025.

Analyst Group • 25 nov 2024 15:18

Analyst Group Comment on ODI Pharma’s Announcement of Rights Issue

ODI Pharma announced on October 30th that the company has resolved to carry out a rights issue of approximately SEK 4.

Analyst Group • 31 okt 2024 11:04

ODI Pharma: Continued Strong Momentum - Analyst Group

ODI Pharma AB (”ODI Pharma” or the ”Company”) delivered another strong quarter during Q4-23/24 (broken fiscal year), further proving the col...

Analyst Group • 05 sep 2024 15:03

Analyst Group Comment on ODI Pharma’s Quarterly Report

ODI Pharma published on August 29th the company’s Q4-report for 2023/2024, which showed a continued strong momentum.

Analyst Group • 29 aug 2024 15:32

Analyst Group Comment on ODI Pharma’s Strategic Market Entry to Switzerland

ODI Pharma announced on June 25th that the company has completed a first delivery of products to the Swiss market, a new market for ODI Phar...

Analyst Group • 26 jun 2024 13:07

ODI Pharma: Starting 2024 with Significant Growth and Profitability - Analyst Group

The third quarter was a breakthrough quarter for ODI Pharma AB (”ODI Pharma” or the ”Company”), with net sales amounting to SEK 13.

Analyst Group • 07 jun 2024 07:43

Analyst Group Comment on ODI Pharma’s Quarterly Report

ODI Pharma published on May 30 the company’s Q3-report for 2023/2024, which showed a strong financial development.

Analyst Group • 30 maj 2024 15:28

Analyst Group Initiates Equity Research Coverage of ODI Pharma

Analyst Group has entered into an agreement with ODI Pharma on commissioned research, including e.

Analyst Group • 06 maj 2024 09:53